News | Leads Implantable Devices | February 24, 2023

Biotronik Conduction System Pacing Tools Received CE Mark for Left Bundle Branch Area Pacing

Multiple studies show that Biotronik conduction system pacing tools can reliably support left bundle branch area pacing procedures, providing physicians with more treatment options for pacing indications.

Multiple studies show that Biotronik conduction system pacing tools can reliably support left bundle branch area pacing procedures

February 24, 2023 — Biotronik announced that it has received CE approval for the Selectra 3D implant tools to include left bundle branch area pacing (LBBAP) in addition to His-bundle pacing (HBP). Commonly referred to as conduction system pacing (CSP) these two approaches have emerged as a physiologic pacing alternative to avoid dyssynchronous contraction of the heart which can induce various negative long-term effects for patients.1-3   

Approved in 2021 for HBP, Selectra 3D’s safety and effectiveness for CSP has been shown in over 10 studies with more than 1,000 patients. In the multi-center Belgium registry that enrolled 353 patients in eight centers, the use of Selectra 3D for LBBAP showed 95% implant success, low pacing thresholds (0.6 +/- 0.4V at 0.4 ms) that remained stable at 12 months, and a low lead revision rate of 1.4%.4 "With this study we were able to show that left bundle branch area pacing using BIOTRONIK tools is a safe and reliable treatment option. It is associated with high implant success, low pacing thresholds and high safety profile," commented the leading study author Prof. Dr. Jan De Pooter, Cardiology and Electrophysiology at the University Hospital Ghent, Belgium. 

BIiotronik CSP tools include an extensive portfolio of catheters with nine distinct length and curve options that adapt to different patient anatomy. The effectiveness of these different variants was confirmed in a previous study5 showing that the 55mm curve fits for most anatomies, the 40mm curve allows to reach more proximal septal targets, and the 65mm curve more distal septal targets in dilated hearts. Enabling more choices for different patient anatomies, Selectra 3D supported over 90% of CSP procedures successfully. The electrical parameters were optimal at implant and remained stable over a median follow-up of 178 (34-402) days. 

"Both clinical practice and intensive scientific research show the growing role of conduction system pacing. With our extensive CSP product line, we provide the tools that can benefit millions of patients in need of cardiac pacing," said Dr. Andreas Hecker, President CRM/EP at Biotronik. 

For more information: www.biotronik.com 


Related Content

News | Leads Implantable Devices

January 3, 2023 — The market has been studied for the below mentioned-segmentation and regional analysis for North ...

Home January 03, 2023
Home
News | Leads Implantable Devices

September 20, 2019 — BioTrace Medical Inc. announced the company’s key activities at the 31st annual Transcatheter ...

Home September 20, 2019
Home
News | Leads Implantable Devices

August 5, 2019 — Abbott is recalling the Ellipse Implantable Cardioverter Defibrillators (ICDs) because electrical ...

Home August 05, 2019
Home
News | Leads Implantable Devices

May 13, 2019 — BioTrace Medical Inc. announced the company’s Tempo Lead has obtained CE Mark certification in Europe for ...

Home May 13, 2019
Home
Technology | Leads Implantable Devices

May 6, 2019 — Medtronic has received U.S. Food and Drug Administration (FDA) approval for the Attain Stability Quad MRI ...

Home May 06, 2019
Home
News | Leads Implantable Devices

May 24, 2018 - Medtronic plc announced results from a research study demonstrating the feasibility of a novel approach ...

Home May 24, 2018
Home
News | Leads Implantable Devices

May 18, 2018 — Data on the effectiveness of cardiac resynchronization therapy (CRT) in patients with non-left bundle ...

Home May 18, 2018
Home
News | Leads Implantable Devices

June 20, 2017 — BioTrace Medical Inc. announced that the company’s Tempo Temporary Pacing Lead was featured in an oral ...

Home June 20, 2017
Home
Videos | Leads Implantable Devices

Bruce Wilkoff, M.D., director of cardiac pacing and tachyarrhythmia devices at Cleveland Clinic, discusses advancements ...

Home May 25, 2017
Home
Technology | Leads Implantable Devices

May 15, 2017 – The U.S. Food and Drug Administration (FDA) has granted market clearance Medtronic’s portfolio of ...

Home May 15, 2017
Home
Subscribe Now